Optimized Immunoassays Detect HBV in Oral Fluid Samples
|
By LabMedica International staff writers Posted on 05 Sep 2019 |
|
Image: A collection of whole saliva by the Salivette (absorbent) method. (a) Saliva is collected by chewing a cotton wool swab. (b) The swab containing saliva is placed in the tube of Salivette. (c) Centrifugation of the assemblage. (d) Saliva is separated from the swab and is ready for analysis (Photo courtesy of Sarstedt).
It is estimated that there are 257 million chronic hepatitis B (HBV) carriers worldwide, which highlights the substantial health, social, and economic burden of HBV. Screening of infected, cured and vaccinated individuals is necessary to identify the presence of chronically infected reservoirs, immune and susceptible individuals.
Currently, HBV infection diagnosis is performed using serum and plasma samples collected via venipuncture, which can be invasive, expensive, and potentially painful and arduous for some individuals including the elderly, obese, patients receiving hemodialysis, and drug users. In regions where financial resources are scarce, it would be beneficial to use methods with low cost and biological risk, such as oral fluid samples.
Scientists at the Oswaldo Cruz Institute (Rio de Janeiro, Brazil) optimized a commercially available assay for detecting total anti-HBc marker in oral fluid samples and evaluated its utility under real life conditions in different settings for the purposes of prevalence and diagnostic studies. The team collected blood samples, which were centrifuged for serum. Oral fluid was obtained using a commercial Salivette device. All serum samples were submitted to commercial Enzyme immunoassays (EIAs) to detect total anti-HBc antibodies directed against HBV surface antigen (anti-HBs) and HBsAg. All oral fluid samples were also tested with the Diasorin EIA ETI-AB-COREK-PLUS, designed to detect total anti-HBc in serum.
Optimization found the best elution buffer was PBS/BSA 0.5% and the best oral fluid sample volume was 100 µL. The team used these optimized parameters, 1,085 of the samples collected from the 1,296 participants did not detect anti-Hbc; in 211 samples, anti-HBc was detected. The oral fluid sensitivity was 52.6% and specificity was 96%. Sensitivity was higher in patients presenting with an active HBV infection compared with anti-HBc isolate and past infection, 92.7%, 43.2%, and 36.9%, respectively. In addition, sensitivity was higher in participants without active hepatitis C virus infection and also in participants who used injection drugs (85.9%).
The authors concluded that it was possible to optimize a commercial enzyme-linked immunosorbent assay for detecting anti-HBc in oral fluid samples where the highest concordance was found in ambulatory settings and among individuals with active infection. The study was published on July 17, 2019, in the journal BMC Infectious Diseases.
Related Links:
Oswaldo Cruz Institute
Currently, HBV infection diagnosis is performed using serum and plasma samples collected via venipuncture, which can be invasive, expensive, and potentially painful and arduous for some individuals including the elderly, obese, patients receiving hemodialysis, and drug users. In regions where financial resources are scarce, it would be beneficial to use methods with low cost and biological risk, such as oral fluid samples.
Scientists at the Oswaldo Cruz Institute (Rio de Janeiro, Brazil) optimized a commercially available assay for detecting total anti-HBc marker in oral fluid samples and evaluated its utility under real life conditions in different settings for the purposes of prevalence and diagnostic studies. The team collected blood samples, which were centrifuged for serum. Oral fluid was obtained using a commercial Salivette device. All serum samples were submitted to commercial Enzyme immunoassays (EIAs) to detect total anti-HBc antibodies directed against HBV surface antigen (anti-HBs) and HBsAg. All oral fluid samples were also tested with the Diasorin EIA ETI-AB-COREK-PLUS, designed to detect total anti-HBc in serum.
Optimization found the best elution buffer was PBS/BSA 0.5% and the best oral fluid sample volume was 100 µL. The team used these optimized parameters, 1,085 of the samples collected from the 1,296 participants did not detect anti-Hbc; in 211 samples, anti-HBc was detected. The oral fluid sensitivity was 52.6% and specificity was 96%. Sensitivity was higher in patients presenting with an active HBV infection compared with anti-HBc isolate and past infection, 92.7%, 43.2%, and 36.9%, respectively. In addition, sensitivity was higher in participants without active hepatitis C virus infection and also in participants who used injection drugs (85.9%).
The authors concluded that it was possible to optimize a commercial enzyme-linked immunosorbent assay for detecting anti-HBc in oral fluid samples where the highest concordance was found in ambulatory settings and among individuals with active infection. The study was published on July 17, 2019, in the journal BMC Infectious Diseases.
Related Links:
Oswaldo Cruz Institute
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Latest Microbiology News
- Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
- Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
- Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection
- Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
- Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
- Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
- FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
- Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus
- Genetic Studies Uncover Mechanisms Driving Drug Resistance in Superbugs
Channels
Clinical Chemistry
view channel
New One-Step Syphilis Test Could Enable Earlier Detection and Faster Treatment
Syphilis can be difficult to diagnose because its symptoms may resemble other diseases and appear and disappear without treatment. Undetected infection can continue causing harm, spread to partners and... Read more
Multimodal Clinical Data Models Predict Cachexia Risk Across Cancers
Cancer cachexia is a severe wasting syndrome that affects roughly half of patients with cancer and cannot be reversed simply by increasing food intake. It can reduce treatment tolerance, impair quality... Read more
Molecular Diagnostics
view channel
RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more
Modeling Study Shows Blood-Based CRC Screening Could Prevent More Deaths Than Stool Tests
Colorectal cancer (CRC) screening depends on patient participation and completion of follow-up colonoscopy after an abnormal noninvasive result. Access barriers can make both steps difficult, particularly... Read more
Hematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read more
Immunology
view channel
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read more
Pathology
view channel
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read more
Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
Digital pathology is reshaping how laboratories manage case review, image analysis, and collaboration. As diagnostic workflows become more complex, pathology teams need platforms that can support digital... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more
Industry
view channel
Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care
Tuberculosis remains a major global infectious disease challenge despite declining deaths. In 2024, an estimated 10.7 million people worldwide developed the disease and nearly 1.2 million died from it.... Read more
